Articles tagged with Breast Cancer
A study found a potential link between alcohol consumption and breast cancer, suggesting that the protein CYP2E1 plays a direct role in explaining the long-established risk factor. Women who naturally express higher levels of CYP2E1 and consume alcohol may be at a greater risk for developing breast cancer.
A study found high levels of TRAIL protein in human milk, which may contribute to its anticancer properties. Researchers detected 400- and 100-fold higher levels of TRAIL in colostrum and mature breast milk than in blood.
A recent study by Maggie Louie reveals that prolonged exposure to cadmium can cause breast cancer cells to become more aggressive and develop malignant characteristics. The researchers found that even small concentrations of cadmium at chronic exposures can contribute to the progression of breast cancer.
Researchers at IBN discover engineered human stem cells can target and inhibit tumor growth, prolonging survival in mice with breast tumors. This finding paves the way for innovative stem cell-based therapies, offering a promising alternative to conventional cancer treatment.
Researchers discover Perp, a protein involved in cellular 'glue', plays dual role in preventing breast cancer. Abnormal levels of Perp linked to enhanced inflammatory response and tumor development.
New research from Lund University identifies a potential cancer treatment by targeting a protein involved in cell division. The study found that blocking this protein could kill cancer cells while sparing healthy ones.
Researchers found that two-thirds of breast cancer survivors experience moderate-level cancer worry three years after treatment, with fatigue and risk perception being significant factors. The study aimed to identify characteristics associated with cancer worry, which can impact health behaviors.
Researchers at Moffitt Cancer Center found that breast cancer survivors who underwent chemotherapy and/or radiation therapy performed worse on cognitive tests than those who did not have cancer. The study's findings suggest long-term cognitive effects of these therapies need further investigation.
Researchers have reclassified breast cancer into 10 subtypes based on genetic features, allowing doctors to predict tumor behavior and tailor treatment. The study also discovered several completely new genes linked to breast cancer, which could lead to the development of new drugs and treatments.
A recent study published in PNAS contradicts the prevailing belief that basal-like cells are responsible for invasive tumors. Luminal-like cells, previously thought to lack stem cell properties, have been found to be highly tumorigenic and capable of generating larger tumors than their basal-like counterparts.
Researchers at Case Western Reserve University have developed a magnetic nanochain delivery system that explodes chemotherapy drugs inside tumors, killing cancer cells more efficiently. The technology reduced tumor growth by up to 90% and increased survival rates in rats with triple-negative breast cancer.
The Prospective Surveillance Model is a novel approach to managing pathological conditions resulting from cancer treatment by promoting early identification and treatment of known side effects. The goal of the model is to identify impairment at the earliest onset, alleviate impairment, or prevent it from progressing.
Researchers at Mayo Clinic have discovered a new class of molecular mutation in various forms of breast cancer, which may shed light on the development and growth of different types of breast tumors. Fusion transcripts, the mutated forms of RNA, could provide a way to identify tumor subtypes and offer new strategies for treatment.
A recent study found that men who reported the highest levels of stress in relation to their wives' breast cancer were at the highest risk for physical symptoms and weaker immune responses. The researchers suggest that clinicians caring for breast cancer patients could help their patients by considering the caregivers' health as well.
A web-based intervention tool called Guide to Decide helped post-menopausal women understand their breast cancer options and feel comfortable with their choice, leading to less uncertainty and increased decision-making. The study found that tailored information reduced anxiety and improved decision outcomes for high-risk women.
A University of Miami study shows that physically active women with non-metastatic breast cancer experience reduced depression and fatigue, as well as improved quality of life. Women who engaged in regular physical activity reported less debilitating fatigue and an enhanced ability to perform daily activities.
A team from UNC Health Care has developed a broad-based test to measure the activation of protein kinases, enabling the measurement of drug resistance in cancer. The test can identify combinations of drugs that block resistance, offering personalized therapies for breast cancer.
Researchers from the University of Hull have identified a family of proteins associated with chemotherapy resistance in breast cancer patients. The 14-3-3 protein family was found to be twice as prevalent in resistant patients, suggesting its potential use as a predictive test for clinical decision-making.
Research suggests stress can cause cognitive decline in women with breast cancer, regardless of treatment status. Women with passive coping strategies and high stress levels experience impaired memory and attention. Effective coping strategies are essential to maintaining cognitive function.
A new breast cancer rehabilitation model proposes a prospective surveillance approach to address physical issues, promoting reduced impairment, improved function, and increased exercise participation. The model aims to integrate disease treatment with rehabilitation and exercise interventions for better survivorship care.
Combining antiangiogenesis drugs with smaller nanomedicines may enhance treatment effectiveness for certain cancers. Vascular normalization temporarily decreases tumor blood vessel diameter, improving drug penetration of smaller particles but not larger molecules.
A new study finds that more than 60% of breast cancer survivors experience treatment-related complications even six years after their diagnosis. The study provides a comprehensive snapshot of the physical late effects of breast cancer treatment and outlines a model for monitoring and preventing these conditions.
Scientists have identified bimodal genes acting as molecular switches in ovarian cancer, providing potential targets for clinical prognostic and diagnostic testing. These gene expressions are associated with different tumor subtypes and patient survival outcomes.
A new study by Rush University Medical Center found that lung cancer screening with low-dose spiral CT scans can detect early-stage disease and reduce cancer-related deaths. The study estimates that commercial insurers should consider providing this benefit to high-risk individuals, which could lead to significant cost savings.
A study found that women with false-positive mammography results have a statistically significant higher risk of developing breast cancer compared to those who test negative. The long-term excess risk underscores the need for regular screenings despite potential anxiety from false-positive experiences.
A McGill University team has developed a new microarray technology that can accurately measure multiple proteins in a droplet of blood to detect breast cancer. The test, which uses a 'fingerprint' approach, showed promise in classifying patients with estrogen receptor-positive breast cancer.
Researchers at Fox Chase Cancer Center have developed a new cell and animal model of inflammatory breast cancer, which may provide a better understanding of the disease and help with developing effective interventions. The model recapitulates aggressive metastasis and cancer stem cell activity associated with poor outcomes in patients.
A new study has found a link between injectable contraceptives and increased breast cancer risk in young women, particularly those who have recently used the birth control method. Recent DMPA use for over a year was associated with a 2.2-fold increased risk of invasive breast cancer, which dissipates after discontinuation.
A large-scale genetic study reveals that triple negative breast cancer tumours exhibit a continuum of different types, making them difficult to treat. The discovery highlights the importance of tailoring cancer drug treatment to individual tumour profiles.
African American women are more likely to have estrogen receptor (ER) negative breast cancer due to genetic variations in the vitamin D receptor. Vitamin D deficiency is also common among these women, but those with specific genetic variations may have reduced risk.
A study found that combining annual mammography with screening ultrasound in women at high risk for breast cancer and dense breasts resulted in a higher detection rate of incident breast cancers. Supplemental MRI further increased cancer detection, adding 14.7 cases per 1,000 women.
Researchers at Thomas Jefferson University found that eliminating the 'good cholesterol' receptor SR-BI can decrease breast cancer cell growth and tumor formation in mice. This study suggests a potential new approach to fighting breast cancer, with further research needed to fully characterize its role.
Researchers found that between 15% and 25% of breast cancer cases are overdiagnosed due to routine mammography screening. This can lead to unnecessary treatments and stress for women, with only a small reduction in mortality rates.
A clinical trial involving 14 TNBC tumors explores the use of whole-genome sequencing to identify potential treatment options. The study aims to advance personalized medicine and guide treatment for individual patients.
A new study in animal models found that women with breast cancer who began eating soy as an adult may develop a tumor more resistant to treatment. The research suggests that stopping soy intake if diagnosed with breast cancer could be beneficial.
A new study in Annals of Internal Medicine reveals that mammography screening may lead to overdiagnosis of breast cancer, potentially causing unnecessary anxiety and altered quality of life. Meanwhile, an international network of experts proposes minimum standards for guideline development to ensure high-quality evidence-based care. Ad...
A survey of mothers tested for hereditary breast cancer risk genes and their partners found unmet needs in making well-informed decisions about family communication. Genetic counseling should provide assistance to parents in disclosing risk information to children, the article proposes.
Researchers created transgenic mice with light-emitting lymphatic vessels to study tumor cell dissemination. The technique detects lymph node invasion by tumor cells, providing a unique tool for studying inflammation and metastasis.
A new study found that a protein called SIX1 plays a critical role in early stage metastasis, especially lymphatic metastasis, in breast cancer. The study identified the SIX1-VEGF-C pathway as an important signaling pathway involved in breast cancer metastasis.
A new study by Georgetown Lombardi Comprehensive Cancer Center finds that using a c-Src inhibitor like PP2 in combination with estrogen may cancel out the benefits of estrogen therapy. Instead, a c-Src inhibitor alone may offer an alternative treatment option for breast cancer patients whose tumors no longer respond to tamoxifen or aro...
Researchers found four proteins dysregulated by the PI3K/mTOR pathway associated with poor survival in hormone receptor-positive breast cancer. These findings suggest potential new prognostic factors and therapeutic targets for treatment.
A study by University of North Carolina at Charlotte researchers confirms the connection between metastatic breast cancer and autoimmune arthritis. Mast cells play a critical role in facilitating breast cancer metastasis, with SCF/Kit signaling inducing mast cell differentiation in arthritic conditions. This finding suggests a potentia...
Researchers found that patients with high levels of Aurora-A protein had shorter survival after surgery compared to those with normal levels. This suggests Aurora-A plays a role in head and neck cancer development and could serve as a new treatment target.
The University of Arizona has received a $2 million grant from the National Institutes of Health to develop an innovative magnetic resonance imaging method for measuring pH levels in tumors. This technique aims to personalize cancer treatments, such as baking soda therapy, and predict their effectiveness before treatment begins.
A new study identified a key mechanism driving breast cancer invasion and linked it to ErbB2 amplification and cathepsin expression. This research offers insights into the molecular basis of ErbB2-induced malignancy and potential therapeutic targets for treatment-resistant forms.
Researchers have identified a new breast cancer risk gene, XRCC2, using advanced genetic sequencing technology. The gene's mutations explain a proportion of breast cancers that run in families with no known genetic cause, particularly those diagnosed at an early age.
A new breast cancer susceptibility gene, XRCC2, has been discovered by researchers at the University of Utah Health. The study found that mutations in this gene increase breast cancer risk, providing a new target for chemotherapy and improving diagnostic accuracy.
Breast cancer patients treated with IMRT had lower incidence of acute and chronic toxicities compared to standard WBI. Larger breasted women also benefited from reduced toxicities with IMRT.
A new blood test has been developed to detect breast cancer recurrence up to 11-12 months before current tests, using a combination of biomarkers and mass spectrometry. The test shows promise for improving therapy outcomes by enabling earlier detection and treatment.
Researchers at the University of Alberta discovered that some breast cancer tumors with weak 'survival' systems responded better to taxane chemotherapy than those with strong survival systems. This finding could lead to new strategies for identifying patients who may not respond to this common treatment.
A Stanford study shows a single antibody can shrink human tumors in mice by blocking a protein flag on cancer cells. The treatment achieved dramatic responses in various types of cancers, including breast, ovarian, colon, bladder, and prostate cancers.
A new study reveals that only four percent of young women with cancer preserve their fertility during treatments. Women from specific socio-demographic groups are more likely to receive counseling and take action.
Percutaneous cryoablation, an interventional radiology procedure, uses tiny probes to freeze and destroy tumors in metastatic breast cancer. The treatment has been shown to provide a valuable alternative to other therapies with minimal side effects and reduced recovery time.
A randomised controlled trial found ultrasound-guided surgery excises all cancerous tissue with minimal healthy tissue removal, reducing re-excisions and radiotherapy. The technique enables precise tumour localisation and assessment of surgical margins.
A new study found that overweight and obese women are at higher risk of breast cancer recurrence, regardless of chemotherapy dosage. The study, which analyzed data from 1909 patients, suggests that lifestyle factors can influence cancer prognosis.
Researchers have developed a breast implant with a 'bed-of-nails' surface at the nanoscale that reduces cancer cell growth and promotes healthy endothelial breast cells. The implant's unique surface features deter cancerous cells from dwelling and thriving, offering a promising alternative to traditional treatments.
A national clinical trial found that preoperative aromatase inhibitors enabled postmenopausal women with estrogen receptor-positive breast cancer to have lumpectomy instead of mastectomy. The treatment increased the likelihood of breast-conserving surgery, sparing women's breasts.
A phase III clinical trial found that the combination of everolimus and exemestane improved bone strength and reduced the chance of cancer spreading in the bone. The treatment also showed a lower rate of further tumour growth and more difficult metastases to occur.
Scientists have identified a genetic marker that predicts which breast and ovarian cancers will respond to platinum-based chemotherapies. The marker, found on chromosomes within cancer cells, flags tumors unable to repair DNA damage caused by platinum agents, offering new hope for aggressive triple-negative breast cancer patients.
Researchers found 22% of TNBC patients had the androgen receptor, which was linked to more aggressive cancer but not necessarily worse survival rates. The study suggests targeting the androgen receptor could be a new way to treat TNBC.